Research Topics
| Yuti ChernajovskySummaryAffiliation: Queen Mary Country: UK Publications
| Collaborators
|
Detail Information
Publications
Molecular engineering of short half-life small peptides (VIP, ?MSH and ?3MSH) fused to latency-associated peptide results in improved anti-inflammatory therapeuticsSandrine Vessillier
Correspondence to Professor Yuti Chernajovsky, Bone and Joint Research Unit, William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, London EC1M 6BQ, UK
Ann Rheum Dis 71:143-9. 2012..This design improves efficacy, overcoming the limitations to their clinical use...- Inhibition of established collagen-induced arthritis with a tumour necrosis factor-alpha inhibitor expressed from a self-contained doxycycline regulated plasmidDavid J Gould
Bone and Joint Research Unit, Barts and The London, Queen Mary's School of Medicine and Dentistry, University of London, London, UK
Arthritis Res Ther 6:R103-13. 2004..The observations of this study are considered with regard to the disease model, the magnitude of gene regulation, and the path to clinical application... - Gene therapy for autoimmune diseases: quo vadis?Yuti Chernajovsky
Bone and Joint Research Unit, William Harvey Research Institute, Barts and The London, Queen Mary s School of Medicine and Dentistry, University of London, Charterhouse Square, London EC1M 6BQ, UK
Nat Rev Immunol 4:800-11. 2004..We focus our attention on multiple sclerosis, type 1 diabetes and rheumatoid arthritis... - Development of new molecules, vectors and cells for therapy of arthritisYuti Chernajovsky
Bone and Joint Research Unit, Barts and The London, Queen Mary's School of Medicine and Dentistry, University of London, Charterhouse Square, London EC1 M 6BQ, UK
Joint Bone Spine 70:474-6. 2003 - Gene therapy for arthritis--where do we stand?Yuti Chernajovsky
William Harvey Research Institute, Barts and The London, Queen Mary s School of Medicine and Dentistry, University of London, London, UK
Arthritis Res Ther 7:227-9. 2005..Also, it will need to be demonstrated that gene therapy for the arthritides is economically feasible and that patient populations worldwide will be able to access these treatments... - Fighting cancer with oncolytic virusesYuti Chernajovsky
Bone and Joint Research Unit, William Harvey Research Institute, Barts and The London, Queen Mary's School of Medicine and Dentistry, Queen Mary, University of London, London EC1M 6BQ
BMJ 332:170-2. 2006 - Advances in understanding the genetic basis of rheumatoid arthritis and osteoarthritis: implications for therapyYuti Chernajovsky
Bone and Joint Research Unit, Queen Mary s School of Medicine and Dentistry, Barts and The London, University of London, London, UK
Am J Pharmacogenomics 2:223-34. 2002..In the last few years, polymorphisms in such genes have indeed been identified as risk factors for rheumatic diseases... - Gene therapy with an improved doxycycline-regulated plasmid encoding a tumour necrosis factor-alpha inhibitor in experimental arthritisDavid Gould
Bone and Joint Research Unit, Barts and The London, Queen Mary s School of Medicine and Dentistry, Charterhouse Square, University of London, London, UK
Arthritis Res Ther 9:R7. 2007..Vectors with similar regulation characteristics may be suitable for clinical application... - Interferon-beta gene therapy for the treatment of arthritisYuti Chernajovsky
Bone and Joint Research Unit, William Harvey Research Institute, Barts and Royal London Medical School, Queen Mary, University of London, UK
Methods Mol Biol 215:171-80. 2003 - Latent cytokines: development of novel cleavage sites and kinetic analysis of their differential sensitivity to MMP-1 and MMP-3Sandrine Vessillier
Bone and Joint Research Unit, William Harvey Research Institute, Barts and The London, Queen Mary's School of Medicine and Dentistry, University of London, Charterhouse Square, London EC1M 6BQ, UK
Protein Eng Des Sel 17:829-35. 2004..These data suggest that this strategy could be useful for improving the effectiveness of the delivery and targeting of protein therapeutics... - Methods for targeting biologicals to specific disease sitesAhuva Nissim
Bone and Joint Research Unit, William Harvey Research Institute, Barts and The London, Queen Mary's School of Medicine and Dentistry, University of London, Charterhouse Square, London EC1M 6BQ, UK
Trends Mol Med 10:269-74. 2004..Because these technologies are based on the expression of fusion proteins, their application can be extended to other biologicals and can be delivered by gene therapy... - Human single-chain variable fragment that specifically targets arthritic cartilageChris Hughes
Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK
Arthritis Rheum 62:1007-16. 2010.... - Generation of neoantigenic epitopes after posttranslational modification of type II collagen by factors present within the inflamed jointAhuva Nissim
Bones and Joint Research Unit, Barts and The London, University of London, London, UK
Arthritis Rheum 52:3829-38. 2005..The aim of this investigation was to determine if CII, modified by reactive oxidant species present within the inflamed joint, could generate neoantigenic epitopes... - Novel delivery methods to achieve immunomodulationDavid J Gould
Bone and Joint Research Unit, William Harvey Research Institute, Barts and The London, Queen Mary s School of Medicine and Dentistry, University of London, Charterhouse Square, London EC1M 6BQ, United Kingdom
Curr Opin Pharmacol 7:445-50. 2007..The application of these technologies has entered the clinical arena and is having a positive impact on the treatment and prevention of human diseases... - Regulation of expression and function of Lck tyrosine kinase by high cell densityPatricia Ozegbe
Bone and Joint Research Unit, William Harvey Research Institute, Queen Mary's School of Medicine and Dentistry, University of London, London, UK
Mol Membr Biol 22:363-72. 2005.... - A novel hybrid promoter responsive to pathophysiological and pharmacological regulationMaria C Subang
Bone and Joint Research Unit, Barts and the London School of Medicine and Dentistry, William Harvey Research Institute, Queen Mary University of London, Charterhouse Square, London, UK
J Mol Med (Berl) 90:401-11. 2012.... - Targeting cytokines to inflammation sitesGill Adams
Bone and Joint Research Unit, William Harvey Research Institute, St. Bartholomew's and Royal London School of Medicine and Dentistry, Queen Mary, University of London, Charterhouse Square, London EC1M 6BQ, UK
Nat Biotechnol 21:1314-20. 2003..Intramuscular injection in arthritic mice of plasmid DNA encoding these constructs demonstrated a greater therapeutic effect of the latent as compared to the active forms... - A chimeric receptor of the insulin-like growth factor receptor type 1 (IGFR1) and a single chain antibody specific to myelin oligodendrocyte glycoprotein activates the IGF1R signalling cascade in CG4 oligodendrocyte progenitorsAlexander Annenkov
Bone and Joint Research Unit, William Harvey Research Institute, Bart s and the London School of Medicine, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK
Biochim Biophys Acta 1813:1428-37. 2011..Another ChR, which contains a segment of the ?-chain ectodomain, was produced in an attempt to recapitulate some of these conformational changes, but proved non-functional... - Clustering of immunoreceptor tyrosine-based activation motif-containing signalling subunits in CD4(+) T cells is an optimal signal for IFN-gamma production, but not for the production of IL-4Alexander E Annenkov
Bone and Joint Research Unit, St Bartholomew's and Royal London School of Medicine and Dentistry, Queen Mary, University of London, London EC1M 6BQ, UK
Int Immunol 15:665-77. 2003..The significance of these data for the development of anti-inflammatory gene therapy based on CD4(+) T cells targeted to a tissue-specific protein is discussed... - Abnormal tumor necrosis factor receptor I cell surface expression and NF-kappaB activation in tumor necrosis factor receptor-associated periodic syndromeBelinda Nedjai
Barts and The London, Queen Mary s School of Medicine and Dentistry, University of London, London, UK
Arthritis Rheum 58:273-83. 2008.... - Tumor necrosis factor receptor I from patients with tumor necrosis factor receptor-associated periodic syndrome interacts with wild-type tumor necrosis factor receptor I and induces ligand-independent NF-kappaB activationNasim Yousaf
Barts and the London Queen Mary's School of Medicine and Dentistry, University of London, London, UK
Arthritis Rheum 52:2906-16. 2005.... - Endogenous GATA factors bind the core sequence of the tetO and influence gene regulation with the tetracycline systemDavid J Gould
Bone and Joint Research Unit, Barts and The London, Queen Mary s School of Medicine and Dentistry, London University, Charterhouse Square, London EC1M 6BQ, UK
Mol Ther 10:127-38. 2004..The findings of this study may have implications for the application of the tetracycline system in gene therapy... - The differential contribution of tumour necrosis factor to thermal and mechanical hyperalgesia during chronic inflammationJulia J Inglis
Bone and Joint Research Unit, Barts and the London School of Medicine and Dentistry, John Vane Science Centre, London, UK
Arthritis Res Ther 7:R807-16. 2005..These results highlight the potential for TNF to play a vital role in inflammatory hyperalgesia, both by a direct action on neurons via TNFR1 and by facilitating the accumulation of macrophages in the DRG via a TNFR2-mediated pathway... - Engineering stem cells for therapyMarinela Mendez-Pertuz
Bone and Joint Research Unit, Barts and the London Queen Mary's School of Medicine and Dentistry, University of London, Charterhouse Square, London EC1M 6BQ, UK
Regen Med 1:575-87. 2006.... - Highly efficient gene transfer into antigen-specific primary mouse lymphocytes with replication-deficient retrovirus expressing the 10A1 envelope proteinAlexander E Annenkov
Bone and Joint Research Unit, St Bartholomew's and Royal London School of Medicine and Dentistry, Queen Mary, University of London, Charterhouse Square, London EC1M 6BQ, UK
J Gene Med 4:133-40. 2002..CONCLUSIONS: This protocol allows for the generation of packaging cells producing high titres of retrovirus vector. The 10A1 envelope protein is superior to the ecotropic one for the transduction of mouse lymphocytes... - Fibroblast-mediated delivery of GDNF induces neuronal-like outgrowth in PC12 cellsKirsten Wissel
Department of Otolaryngology, Medical School of Hannover, Hannover, Germany
Otol Neurotol 29:475-81. 2008..Recombinantly modified cells deliver neurotrophic factors with the capacity to induce differentiation and the outgrowth of neurites of rat pheochromocytoma cells 12 (PC12) serving as a neuronal model... - T cell receptor zeta reconstitution fails to restore responses of T cells rendered hyporesponsive by tumor necrosis factor alphaJoanna M Clark
Kennedy Institute of Rheumatology Division, Faculty of Medicine, Imperial College London, 1 Aspenlea Road, Hammersmith, London W6 8LH, United Kingdom
Proc Natl Acad Sci U S A 101:1696-701. 2004..We provide additional evidence that TNF also uncouples distal TCR signaling pathways independently of its effects on TCRzeta expression... - A novel biological activity for galectin-1: inhibition of leukocyte-endothelial cell interactions in experimental inflammationMylinh La
Department of Biochemical Pharmacology and the Bone and Joint Research Unit, The William Harvey Research Institute, London, United Kingdom
Am J Pathol 163:1505-15. 2003..It is possible that endogenous Gal-1 may be part of a novel anti-inflammatory loop in which the endothelium is the source of the protein and the migrating PMNs the target for its anti-inflammatory action...